Progyny furnishes press release and earnings deck: Exhibits 99.1 & 99.2

Rhea-AI Filing Summary

Progyny (PGNY) furnished an update on its latest results. The company announced financial results for the fiscal quarter ended September 30, 2025 and made these materials available to investors.

A press release and a supplemental earnings presentation were furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are also accessible via the investor relations site. The information furnished under Items 2.02 and 7.01, including these exhibits, is provided as furnished, not filed.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/06/2025 - 04:14 PM Learn about SEC filing dates

0001551306false00015513062025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Progyny, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-39100			27-2220139
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1359 Broadway New York, New York			10018
(Address of Principal Executive Offices)			(Zip Code)

(212) 888-3124

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

PGNY

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition and

Item 7.01 Regulation FD Disclosure.

On November 6, 2025, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

In addition to the press release, a supplemental earnings presentation will be made available on the Company’s investor relations page at investors.progyny.com. A copy of this supplemental earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

The information furnished under Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of Progyny, Inc. dated November 6, 2025
99.2						Third Quarter Earnings Supplemental Presentation
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Progyny, Inc.
Date: November 6, 2025
			By:			/s/ Peter Anevski
						Peter Anevski
						Chief Executive Officer

FAQ

What did Progyny (PGNY) announce in its Form 8-K?

Progyny announced financial results for the fiscal quarter ended September 30, 2025 and furnished related materials.

Which exhibits accompany Progyny’s results announcement?

The company furnished a press release as Exhibit 99.1 and a supplemental earnings presentation as Exhibit 99.2.

Are the results materials considered filed with the SEC?

No. Information under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is furnished and not filed.

Where can investors access Progyny’s earnings presentation?

The supplemental earnings presentation is available on the company’s investor relations page at investors.progyny.com.

What period do the announced results cover for PGNY?

The results cover the fiscal quarter ended September 30, 2025.

When was the announcement made?

Progyny made the announcement on November 6, 2025.